BR0314769A - Construção de ácido nucleico, método de gerar a mesma, partìculas revestidas adequadas para a liberação a partir de um dispositivo de liberação mediada por partìcula, receptáculo de dosagem para um dispositivo de liberação mediada por partìcula, dispositivo de liberação mediada por partìcula, e, métodos de obter a expressão em uma célula de mamìfero de um polipeptìdeo de interesse e de imunização por ácido nucleico - Google Patents

Construção de ácido nucleico, método de gerar a mesma, partìculas revestidas adequadas para a liberação a partir de um dispositivo de liberação mediada por partìcula, receptáculo de dosagem para um dispositivo de liberação mediada por partìcula, dispositivo de liberação mediada por partìcula, e, métodos de obter a expressão em uma célula de mamìfero de um polipeptìdeo de interesse e de imunização por ácido nucleico

Info

Publication number
BR0314769A
BR0314769A BR0314769-0A BR0314769A BR0314769A BR 0314769 A BR0314769 A BR 0314769A BR 0314769 A BR0314769 A BR 0314769A BR 0314769 A BR0314769 A BR 0314769A
Authority
BR
Brazil
Prior art keywords
nucleic acid
particle
release device
mediated release
generating
Prior art date
Application number
BR0314769-0A
Other languages
English (en)
Inventor
Ralph Patrick Braun
Original Assignee
Powderject Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Powderject Res Ltd filed Critical Powderject Res Ltd
Publication of BR0314769A publication Critical patent/BR0314769A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/869—Herpesviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/869—Herpesviral vectors
    • C12N15/8695—Herpes simplex virus-based vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

"CONSTRUçãO DE áCIDO NUCLEICO, MéTODO DE GERAR A MESMA, PARTìCULAS REVESTIDAS ADEQUADAS PARA A LIBERAçãO A PARTIR DE UM DISPOSITIVO DE LIBERAçãO MEDIADA POR PARTìCULA, RECEPTáCULO DE DOSAGEM PARA UM DISPOSITIVO DE LIBERAçãO MEDIADA POR PARTìCULA, DISPOSITIVO DE LIBERAçãO MEDIADA POR PARTìCULA, E, MéTODOS DE OBTER A EXPRESSãO EM UMA CéLULA DE MAMìFERO DE UM POLIPEPTìDEO DE INTERESSE E DE IMUNIZAçãO POR áCIDO NUCLEICO". As construções de ácido nucleico que compreendem ácido nucleico genómico viral que compreende pelo menos duas unidades reguladoras de expressão de gene endógeno que cada uma compreende um promotor endógeno onde os promotores endógenos das unidades são ativos na mesma fase no ciclo de vida viral do vírus da qual o ácido nucleico genómico viral é derivado são fornecidos. As unidades reguladoras da expressão de gene endógeno são usadas para expressar seq³ências codificadoras heterólogas escolhidas particulares e em particular para expressar antígenos heterólogos. As construções podem ser usadas em uma vacina para gerar uma resposta imune contra os antígenos heterólogos e em particular podem ser usadas em uma vacina de DNA. Os métodos para gerar as construções e meios para a sua administração também são fornecidos.
BR0314769-0A 2002-09-27 2003-09-29 Construção de ácido nucleico, método de gerar a mesma, partìculas revestidas adequadas para a liberação a partir de um dispositivo de liberação mediada por partìcula, receptáculo de dosagem para um dispositivo de liberação mediada por partìcula, dispositivo de liberação mediada por partìcula, e, métodos de obter a expressão em uma célula de mamìfero de um polipeptìdeo de interesse e de imunização por ácido nucleico BR0314769A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41408902P 2002-09-27 2002-09-27
PCT/GB2003/004218 WO2004029258A1 (en) 2002-09-27 2003-09-29 Nucleic acid constructs for gene expression

Publications (1)

Publication Number Publication Date
BR0314769A true BR0314769A (pt) 2005-07-26

Family

ID=32043343

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0314769-0A BR0314769A (pt) 2002-09-27 2003-09-29 Construção de ácido nucleico, método de gerar a mesma, partìculas revestidas adequadas para a liberação a partir de um dispositivo de liberação mediada por partìcula, receptáculo de dosagem para um dispositivo de liberação mediada por partìcula, dispositivo de liberação mediada por partìcula, e, métodos de obter a expressão em uma célula de mamìfero de um polipeptìdeo de interesse e de imunização por ácido nucleico

Country Status (16)

Country Link
US (1) US20050272030A1 (pt)
EP (1) EP1546347A1 (pt)
JP (1) JP2006500062A (pt)
KR (1) KR20050062565A (pt)
CN (1) CN1701120A (pt)
AU (1) AU2003269220A1 (pt)
BR (1) BR0314769A (pt)
CA (1) CA2500270A1 (pt)
EA (1) EA008247B1 (pt)
GB (1) GB2409681B (pt)
HK (1) HK1073669A1 (pt)
MX (1) MXPA05003225A (pt)
NZ (1) NZ539647A (pt)
PL (1) PL376053A1 (pt)
WO (1) WO2004029258A1 (pt)
ZA (1) ZA200503377B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9273326B2 (en) 2004-04-30 2016-03-01 The Brigham And Women's Hospital, Inc. Tetracycline-regulated gene expression in HSV-1 vectors
JP2010508828A (ja) * 2006-11-10 2010-03-25 マーシャル，バリー，ジェー． 胃粘膜内へのペプチド送達方法及び装置
WO2011079073A2 (en) * 2009-12-21 2011-06-30 The Brigham And Women's Hospital, Inc. Herpes simplex virus vaccines
WO2011150235A1 (en) * 2010-05-27 2011-12-01 Allertein Therapeutics, Llc Methods and reagents for treating autoimmune disorders and/or graft rejection
JP5957443B2 (ja) * 2011-03-28 2016-07-27 長瀬産業株式会社 フェリチンの製造方法
WO2019152821A1 (en) 2018-02-05 2019-08-08 The Brigham And Women's Hospital, Inc. Recombinant herpes simplex virus-2 expressing glycoprotein b and d antigens
US20210222150A1 (en) * 2018-05-29 2021-07-22 Buck Institute For Research On Aging Gene-drive in dna viruses

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5171568A (en) * 1984-04-06 1992-12-15 Chiron Corporation Recombinant herpes simplex gb-gd vaccine
US5288641A (en) * 1984-06-04 1994-02-22 Arch Development Corporation Herpes Simplex virus as a vector
CA1338800C (en) * 1986-06-17 1996-12-17 Michael Houghton Hepatitis delta and diagnostics and vaccines
US5057540A (en) * 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5162222A (en) * 1989-07-07 1992-11-10 Guarino Linda A Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells or recombinant baculoviruses
US5328688A (en) * 1990-09-10 1994-07-12 Arch Development Corporation Recombinant herpes simplex viruses vaccines and methods
US5919676A (en) * 1993-06-24 1999-07-06 Advec, Inc. Adenoviral vector system comprising Cre-loxP recombination
ES2247248T3 (es) * 1994-01-21 2006-03-01 Powderject Vaccines, Inc. Instrumento de administracion de genes movido por gas comprimido.
FR2715664B1 (fr) * 1994-01-31 1996-04-12 Proteine Performance Sa Baculovirus recombinant et son utilisation pour la production d'anticorps monoclonaux.
US5876923A (en) * 1996-07-26 1999-03-02 Arch Development Corporation Herpes simplex virus ICP4 as an inhibitor of apoptosis
GB9700411D0 (en) * 1997-01-10 1997-02-26 Univ London Eukaryotic gene expression cassette and uses thereof
US5922576A (en) * 1998-02-27 1999-07-13 The John Hopkins University Simplified system for generating recombinant adenoviruses

Also Published As

Publication number Publication date
MXPA05003225A (es) 2005-07-05
US20050272030A1 (en) 2005-12-08
ZA200503377B (en) 2007-11-28
HK1073669A1 (en) 2005-10-14
GB0508088D0 (en) 2005-06-01
EA200500547A1 (ru) 2005-12-29
WO2004029258A1 (en) 2004-04-08
KR20050062565A (ko) 2005-06-23
GB2409681B (en) 2007-03-28
PL376053A1 (en) 2005-12-12
AU2003269220A1 (en) 2004-04-19
GB2409681A (en) 2005-07-06
JP2006500062A (ja) 2006-01-05
CA2500270A1 (en) 2004-04-08
EP1546347A1 (en) 2005-06-29
CN1701120A (zh) 2005-11-23
EA008247B1 (ru) 2007-04-27
NZ539647A (en) 2007-05-31

Similar Documents

Publication Publication Date Title
US20200368333A1 (en) Cmv vectors comprising microrna recognition elements
Huang et al. Effect of influenza virus matrix protein and viral RNA on ribonucleoprotein formation and nuclear export
JP7317017B2 (ja) Ｂ型肝炎ウイルス（ｈｂｖ）ワクチンおよびその使用
US20240066117A1 (en) Hbv vaccines and methods treating hbv
JP2017533702A (ja) 生体分子の免疫細胞への送達
CA2494806A1 (en) Expression vectors encoding epitopes of target-associated antigens
JP2023171680A (ja) Ｈｉｖワクチン並びにその作製方法及び使用方法
Yan et al. Protective immunity to H7N9 influenza viruses elicited by synthetic DNA vaccine
US20100099745A1 (en) Enhancing disease resistance against rna viral infections with intracytoplasmic pathogen sensors
US20210060126A1 (en) Major histocompatibility complex (mhc) compositions and methods of use thereof
Macdonald et al. Harnessing alveolar macrophages for sustained mucosal T-cell recall confers long-term protection to mice against lethal influenza challenge without clinical disease
BR0314769A (pt) Construção de ácido nucleico, método de gerar a mesma, partìculas revestidas adequadas para a liberação a partir de um dispositivo de liberação mediada por partìcula, receptáculo de dosagem para um dispositivo de liberação mediada por partìcula, dispositivo de liberação mediada por partìcula, e, métodos de obter a expressão em uma célula de mamìfero de um polipeptìdeo de interesse e de imunização por ácido nucleico
Goubier et al. Superiority of needle-free transdermal plasmid delivery for the induction of antigen-specific IFNγ T cell responses in the dog
Torres et al. DNA immunization: effect of secretion of DNA-expressed hemagglutinins on antibody responses
EP3402514A1 (en) Methods and compositions for influenza vaccination
ES2581576T3 (es) Polinucleótidos que permiten la expresión y la secreción de pseudovirus recombinantes que contienen epítopos extraños, su producción y utilización
CN116802278A (zh) 溶瘤病毒与经改造的免疫细胞联合治疗肿瘤
Weaver et al. Understanding the focused CD4 T cell response to antigen and pathogenic organisms
EP4017985A1 (en) Modulation of t cell responses by ul18 of human cytomegalovirus
Restifo et al. Enhancing the recognition of tumor associated antigens
Nimmerjahn et al. Efficient generation and expansion of antigen‐specific CD4+ T cells by recombinant influenza viruses
CA3179035A1 (en) Influenza vaccines
Mölder et al. Elicitation of broad CTL response against HIV-1 by the DNA vaccine encoding artificial multi-component fusion protein MultiHIV—Study in domestic pigs
RU2618918C2 (ru) Универсальная противогриппозная вакцина
CN109837245A (zh) 一种tcr敲除的靶向ny-eso-1的t细胞受体基因修饰t细胞及其制备方法和应用

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE 6A. E 7A. ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2069 DE 31/08/2010.